Artera vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 52)
Artera logo

Artera

GrowthHealthTech

Patient Communication Platform

Artera orchestrates automated patient outreach across appointment reminders, care gap campaigns, and post-visit follow-up, coordinating communications across a health system's service lines.

AI VisibilityBeta
Overall Score
C52
Category Rank
#320 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
50
Perplexity
58
Gemini
46

About

Artera's patient communication platform sits above EHR and practice management systems to orchestrate outbound and inbound messaging across a health system's multiple service lines — preventing the communication chaos that occurs when each department independently sends texts and reminders that overwhelm patients and create conflicting instructions. The platform uses AI to personalize message timing, channel (SMS, voice, email), and language to maximize patient response rates while suppressing redundant outreach.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

52
Overall Score
81
#320
Category Rank
#17
71
AI Consensus
71
stable
Trend
stable
50
ChatGPT
80
58
Perplexity
75
46
Gemini
77
51
Claude
86
47
Grok
85

Key Details

Category
Patient Communication Platform
General
Tier
Growth
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Artera
Patient Communication Platform

Integrations

Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.